FDA Approves Preservative-Free Latanoprost Drug for Elevated Intraocular Pressure

The FDA has approved Laboratoires Théa subsidiary Thea Pharma’s Iyuzeh (latanoprost ophthalmic solution) 0.005 percent to reduce elevated intraocular pressure in individuals with open-angle glaucoma or ocular hypertension.

Iyuzeh is a preservative-free formulation of latanoprost that “does not need to be manufactured, distributed, or stored at refrigerated temperatures,” the company said.

The drug, which is sold as Monoprost outside of the U.S., has shown consistent reductions in intraocular pressure in clinical trials in the U.S. and Europe.